Patents Assigned to GlaxoSmithKline LLC
  • Statin and omega-3 fatty acids for reduction of Apo-B levels
    Patent number: 8871800
    Abstract: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: October 28, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Roelof M. L. Rongen, Robert A. Shalwitz, Douglas Kling, Ralph T. Doyle, Jr.
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 8865912
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: October 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Quinazoline compounds
    Patent number: 8859571
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: October 14, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Lara S. Kallander, Brian Griffin Lawhorn, Joanne Philp
  • Method of producing a pharmaceutical product
    Patent number: 8858960
    Abstract: A pharmaceutical and pharmaceutical-like product is provided. The product provides a plurality of components having active agents that are delivered in a single delivery entity or vehicle. The product allows for selective control of the release rates of each of the active agents while still being delivered in a single product.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: October 14, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Steven D. Finkelmeier, Robert Glinecke, Luigi Martini
  • 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives
    Patent number: 8846709
    Abstract: Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Emmanuel Hubert Demont, Katherine Louise Jones, Robert J. Watson
  • Benzimidazoles and related analogs as sirtuin modulators
    Patent number: 8846947
    Abstract: Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Chi B. Vu, Jeremy S. Disch, Pui Yee Ng, Charles A. Blum, Robert B. Perni
  • Indazoles
    Patent number: 8846935
    Abstract: Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Celine Duquenne, Neil Johnson, Steven D. Knight, Louis Lafrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8846024
    Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline LLC
    Inventor: Stephen Moore
  • COMPOSITION
    Publication number: 20140288099
    Abstract: Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
    Type: Application
    Filed: July 19, 2012
    Publication date: September 25, 2014
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Claire Louise Ambery, Christopher David Edwards
  • CANCER TREATMENT METHOD
    Publication number: 20140275107
    Abstract: Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (TPO) receptor agonist to such mammal, suitably a human.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 18, 2014
    Applicant: GlaxoSmithKline LLC
    Inventor: Connie L. ERICKSON-MILLER
  • Methods for detecting protein in plasma
    Patent number: 8835381
    Abstract: The present invention provides methods for detecting protein in plasma comprising contacting said plasma with a protease capable of digesting said protein into at least one detectable fragment and detecting said at least one detectable fragment using high performance liquid chromatography and mass spectroscopy.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: September 16, 2014
    Assignee: Glaxosmithkline LLC
    Inventors: David Richard Citerone, Charles Scott Hottenstein, Jonathan R. Kehler
  • Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer
    Patent number: 8835450
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: September 16, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Melissa Dumble, Tona Gilmer, Rakesh Kumar, Peter F. Lebowitz, Shannon Renae Morris, Sylvie Laquerre
  • External nasal dilator and methods of manufacture
    Patent number: 8834511
    Abstract: The present invention relates to external devices for dilating nasal passageways and to the manufacture thereof. More specifically, the external nasal dilator of the present invention usually comprises a resilient sheet, an adhesive layer, and an adhesive-protecting sheet. In some embodiments of the external nasal dilator, the resilient sheet defines a groove for reducing the peel force that results from bending the dilator over the bridge of the nose. In addition to the groove or in lieu thereof, some embodiments of the external nasal dilator comprise a nasal passage region having a reduced width to reduce the peel force. Finally, the dilator can comprise a sheet of adhesive tape, which in some embodiments can provide an instant tack surface to facilitate application of the dilator.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: September 16, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Randel B. Holmes, Dennis White
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8828430
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis (monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: September 9, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X. Muller, Shivakumar G Kapsi
  • Compounds
    Patent number: 8828384
    Abstract: The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: September 9, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Stephanie Jane Clegg, Eric Dobrzynski, Jonathan H. Ellis, Volker Germaschewski, Alexis Pual Godillot, Zdenka Ludmila Jonak, Alan P. Lewis, John R. White
  • Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators
    Publication number: 20140249147
    Abstract: Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: Charles A. Blum, Stephanie K. Springer, Chi B. Vu
  • Compounds And Methods For Enhancing Innate Immune Responses
    Publication number: 20140249143
    Abstract: Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Anna Lindsey Banka, Janos Botyanszki, Eric Gregory Burroughs, John George Catalano, Wendy Huang Chern, Hamilton D. Dickson, Margaret J. Gartland, Robert Hamatake, Hans Hofland, Jesse Daniel Keicher, Christopher Brooks Moore, John Bradford Shotwell, Matthew David Tallant, Jean-Philippe Therrien, Shihyun You
  • Treatment Of Blood Lipid Abnormalities And Other Conditions
    Publication number: 20140249156
    Abstract: There is provided a method of treatment of a patient suffering from blood lipid abnormality comprises the administration of a GPR119 agonist.
    Type: Application
    Filed: October 31, 2012
    Publication date: September 4, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Kathleen Brown, Andrew James Carpenter, Derek J.R. Nunez, Andrew Young
  • Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction
    Patent number: 8822518
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 2, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Temperature telemetry in processing of material
    Patent number: 8815326
    Abstract: In the process of coating pharmaceutical tablets in a moving bed, the temperature of the tablets is measured by incorporating a temperature transducer in the form of tablet into the bed of tablets, and transmitting temperature data to an external receiver by wireless telemetry.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: August 26, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Zane A. Arp, Christine McDade